To investigate which immune cell subsets could be sources of Fgl2 in patients with cancer, we reanalyzed the publicly available dataset deposited by Combes et al. (51), wherein tumors from a myriad of cancer types were dissociated and populations of conventional T cells (Tconv), regulatory T cells (Tregs), myeloid cells, stromal cells, and tumor cells were sorted for bulk RNA sequencing (Figure 5A). The gene discussed is FGL2; the disease is neoplasm.